Galera Therapeutics, Inc. (GRTX)の価格はいくらですか

Galera Therapeutics, Inc. (GRTX)の価格は$17.15です

Galera Therapeutics, Inc. (GRTX)の時価総額は何ですか

Galera Therapeutics, Inc. (GRTX)の時価総額は$6.51Mです

Galera Therapeutics, Inc.（GRTX）発行済株式数

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

年	発行済株式数	変化
2026 (TTM)	98.62M	80.52%
2024	54.63M	22.64%
2023	44.55M	64.47%
2022	27.09M	5.03%
2021	25.79M	3.70%
2020	24.87M	0.24%
2019	24.81M	28.15%
2018	19.36M	-98.73%
2017	1.52B	0.00%

年

発行済株式数

変化

2026 (TTM)

98.62M

80.52%

2024

54.63M

22.64%

2023

44.55M

64.47%

2022

27.09M

5.03%

2021

25.79M

3.70%

2020

24.87M

0.24%

2019

24.81M

28.15%

2018

19.36M

-98.73%

2017

1.52B

0.00%

企業	発行済株式数	差	国
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	157.45%	US
Argenx SE ARGX.US	62.19M	-36.95%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-100.00%	BE

企業

発行済株式数

差

国